Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications.

ABSTRACT:

Background

Statins have demonstrated protection against aggressive/late-stage and/or lethal prostate cancer (PC), but prior studies are limited by small populations, short follow-up and unequal health-care access. Research has not demonstrated that non-statin lipid-lowering medications (NSLLMs) provide a similar benefit, which would support a cholesterol-based mechanism. We sought to rigorously test the hypothesis that cholesterol-lowering drugs affect PC incidence and severity.

Methods

A retrospective cohort study was conducted by abstracting prescription and health service records for 249,986 Saskatchewan men aged ≥40 years between January 1, 1990 and December 31, 2014 and comparing first-time statin and NSLLM users with age-matched non-users and glaucoma medication (GM) u

SUBMITTER: Van Rompay MI 

PROVIDER: S-EPMC6501826 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature